EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rethinking Pharmacological Management of Scabies: Beyond the First-Line Drug

Gianluca Nazzaro, Andrea Malgesini, Gianluca Tavoletti, Angelo Valerio Marzano

Medicines · 20.11.2026 · 13 (4) · 34

DOI: 10.3390/medicines13040034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicines, online erschienen am 20.11.2026. Verfasst von Gianluca Nazzaro und 3 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Scabies remains one of the most common parasitic skin diseases worldwide and continues to pose a substantial clinical and public health burden despite the availability of effective acaricidal treatments. Over the past decade, increasing reports of treatment failure following topical permethrin have reignited the debate on first-line therapy for scabies. While true acaricide resistance has been proposed as a possible explanation, current evidence remains inconclusive, and many apparent failures are more likely attributable to pseudo-resistance, including incorrect application, poor adherence, reinfestation, untreated contacts, or persistent post-scabetic symptoms. This renewed focus on the relative merits of topical permethrin and oral ivermectin has stimulated important discussions but may also have shifted attention away from the broader determinants of therapeutic success. In this Perspective, we argue that pharmacological efficacy alone does not adequately explain treatment success in routine clinical practice. Factors such as adherence, correct application of topical therapy, management of close contacts, reinfestation, persistent post-scabetic symptoms, and the epidemiological context frequently influence outcomes as much as the intrinsic activity of the acaricidal agent. Consequently, treatment failure often reflects shortcomings in the overall management process rather than true drug failure. We propose that future therapeutic decision-making should move beyond the traditional topical-versus-oral treatment debate toward a precision-based approach to scabies management. This framework encourages clinicians to individualize treatment strategies according to three complementary domains: patient characteristics, disease presentation, and epidemiological setting. Rather than replacing existing guidelines, this approach seeks to optimize their application in real-world practice by integrating pharmacological evidence with patient-centred care and transmission control. Reframing first-line therapy in this way may improve both individual outcomes and broader public health interventions.

Zitieren

APA

Nazzaro, G., Malgesini, A., Tavoletti, G., & Marzano, A. V. (2026). Rethinking Pharmacological Management of Scabies: Beyond the First-Line Drug. Medicines, 13(4), 34. https://doi.org/10.3390/medicines13040034

Vancouver

Nazzaro G, Malgesini A, Tavoletti G, Marzano AV. Rethinking Pharmacological Management of Scabies: Beyond the First-Line Drug. Medicines. 2026;13(4):34. doi:10.3390/medicines13040034

BibTeX
@article{Nazzaro2026,
  author = {Nazzaro, Gianluca and Malgesini, Andrea and Tavoletti, Gianluca and Marzano, Angelo Valerio},
  title = {Rethinking Pharmacological Management of Scabies: Beyond the First-Line Drug},
  journal = {Medicines},
  year = {2026},
  volume = {13},
  number = {4},
  pages = {34},
  doi = {10.3390/medicines13040034}
}
Kostenlos starten →